A call for action: Increasing enrollment of untreated patients with higher‐risk myelodysplastic syndromes in first‐line clinical trials
Sign Up to like & getrecommendations! Published in 2017 at "Cancer"
DOI: 10.1002/cncr.30903
Abstract: Hypomethylating agents (HMAs) have changed the landscape of the management of patients with higher‐risk myelodysplastic syndromes (HR‐MDS). HMAs have improved hematopoiesis and quality of life and, in the case of azacitidine, prolonged survival in a… read more here.
Keywords: line; enrollment; patients higher; higher risk ... See more keywords
Five‐day versus 7‐day treatment regimen with azacitidine in lower risk myelodysplastic syndrome: A phase 2, multicenter, randomized trial
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34492
Abstract: Low‐dose azacitidine (AZA) regimens, primarily 5‐day AZA, have been used in lower risk myelodysplastic syndrome (LrMDS) but they have yet to be directly compared to the standard 7‐day, uninterrupted dosing schedule. read more here.
Keywords: day; five day; risk myelodysplastic; myelodysplastic syndrome ... See more keywords
Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?
Sign Up to like & getrecommendations! Published in 2020 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2020.1730806
Abstract: ABSTRACT Introduction: Myelodysplastic Syndrome (MDS) represents a group of cancers characterized by abnormal blood cell formation and maturation, leading to various degrees of cytopenias and potential transformation to acute myeloid leukemia. Deletion of the long… read more here.
Keywords: syndromes del; myelodysplastic syndromes; risk; higher risk ... See more keywords
How low risk are low risk myelodysplastic syndromes?
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2022.2029698
Abstract: ABSTRACT Introduction Risk stratification is crucial to the appropriate management of many diseases, but in patients with myelodysplastic syndromes (MDS), for whom expected survival can vary greatly, accurate disease prognostication is especially important. This is… read more here.
Keywords: risk low; myelodysplastic syndromes; disease; risk ... See more keywords
Clinical effectiveness and safety of erythropoietin‐stimulating agents for the treatment of low‐ and intermediate‐1−risk myelodysplastic syndrome: a systematic literature review
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Haematology"
DOI: 10.1111/bjh.15707
Abstract: Many patients with lower‐risk myelodysplastic syndrome (MDS) experience anaemia, which has negative consequences. Erythropoiesis‐stimulating agents (ESAs) and their biosimilars are used to treat anaemia in MDS and, currently, epoetin alfa and darbepoetin alfa are commonly… read more here.
Keywords: risk; safety; stimulating agents; myelodysplastic syndrome ... See more keywords
Enhancing our chances of picking a winner in higher‐risk myelodysplastic syndromes
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18240
Abstract: Hypomethylating agents remain the current standard of care for patients with higher‐risk myelodysplastic syndromes. Adès et al. report outcomes from a randomised ‘pick‐a‐winner’ study design that examined the addition of either lenalidomide, valproic acid or… read more here.
Keywords: higher risk; myelodysplastic syndromes; winner; risk myelodysplastic ... See more keywords
Phase Ib study of eltrombopag and azacitidine in patients with high‐risk myelodysplastic syndromes and related disorders (the ELASTIC study)
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18389
Abstract: Treating adverse risk myelodysplastic syndromes with azacitidine exacerbates thrombocytopenia. We report a study of eltrombopag in combination with azacitidine using a 3 + 3 cohort design. Patients with baseline platelets of read more here.
Keywords: myelodysplastic syndromes; risk myelodysplastic; study eltrombopag; phase ... See more keywords
Treatment in patients with acute myeloid leukemia/high-risk myelodysplastic syndrome with hypomethylating agents: Day-hospital management compared to home care setting.
Sign Up to like & getrecommendations! Published in 2023 at "European journal of haematology"
DOI: 10.1111/ejh.14012
Abstract: OBJECTIVES Aim of the study was to evaluate the role of a Domiciliary Hematologic Care Unit (DHCU) compared to standard DH setting in the active frontline treatment with hypomethylating agents (HMAs) +/- venetoclax of frail… read more here.
Keywords: leukemia high; high risk; hypomethylating agents; care ... See more keywords
Dose of deferasirox correlates with its effects, which differ between low‐risk myelodysplastic syndrome and aplastic anaemia
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pharmacy and Therapeutics"
DOI: 10.1111/jcpt.13712
Abstract: Patients with low‐risk myelodysplastic syndrome (MDS) and aplastic anaemia (AA) often need transfusions, which may accelerate iron overload. The aim of this study was to evaluate the efficacy, safety and dose–effect relationships of deferasirox (DFX)… read more here.
Keywords: risk; risk myelodysplastic; low risk; myelodysplastic syndrome ... See more keywords
Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.21.02476
Abstract: Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co‐primary or secondary analyses are not yet… read more here.
Keywords: mds; safety; myelodysplastic syndromes; risk myelodysplastic ... See more keywords
Clinical impact of transformation to acute myeloid leukemia in patients with higher-risk myelodysplastic syndromes.
Sign Up to like & getrecommendations! Published in 2023 at "Future oncology"
DOI: 10.2217/fon-2022-0334
Abstract: Aim: Forty percent of patients with higher-risk myelodysplastic syndromes (HR-MDS) transform to acute myeloid leukemia (AML). Materials & methods: This retrospective study assessed the impact of HR-MDS transformation to AML on OS in a 6-month landmark… read more here.
Keywords: higher risk; myelodysplastic syndromes; risk myelodysplastic; patients higher ... See more keywords